Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer
Shots:
- The P-III trial involves assessing Libtayo (300mg- IV- q3w) as monothx. vs CT in patients with recurrent or metastatic cervical cancer that has progressed on platinum-based CT. The trial enrolled patients regardless of their PD-L1 status
- The results demonstrated a 31% reduction in the risk of death in the total population- improvement in OS- median survival (12.0 mos. vs 8.5mos). The trial will stop early- following the IDMC recommendation
- Libtayo is a fully-human mAb targeting the immune checkpoint receptor PD-1 on T-cells. Both the companies plan the regulatory submission of the therapy in 2021
Ref: Regeneron | Image: Livable Limerick
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com